Clinical Trial

Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated July 24, 2024 (before its estimated October 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is an investigator-initiated, single-arm, exploratory clinical study.The study population consisted of treatment naive advanced esophageal squamous cell carcinoma patients. The purpose of this study was to evaluate the efficacy and safety of immunotherapy combined with chemotherapy and residual lesions irradiation of esophageal squamous cell carcinoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-11-13.
Trial Details
NCT Number NCT06138028
Lead Sponsor Qingdao Central Hospital
Conditions Metastatic Esophageal Squamous Cell Carcinoma
Enrollment 90 participants
Start Date 2023-09-20
Primary Completion 2025-10-31 (estimated)
Study Completion 2026-10-31 (estimated)
Updated on ClinicalTrials.gov 2024-07-24